台灣臨床試驗主持人資料庫|TPIDB

2019-06-01 - 2022-12-31

Phase II

A PHASE 2, OPEN-LABEL, RANDOMIZED, PARALLEL GROUP, CONTROLLED STUDY OF PEMETREXED MAINTENANCE WITH OR WITHOUT ADXS11-001 IMMUNOTHERAPY IN SUBJECTS WITH HUMAN PAPILLOMAVIRUS-POSITIVE, NON-SQUAMOUS, NONSMALL CELL LUNG CARCINOMA FOLLOWING FIRST-LINE INDUCTION CHEMOTHERAPY

Condition/Disease

LUNG CARCINOMA
Test Drug

ADXS11-001

Participate Sites
9Sites

Terminated9Sites

李岡遠

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2017-07-01 - 2019-09-09

Phase III

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Subjects Assessed to be at Imminent Risk for Suicide

Condition/Disease

Major Depressive Disorder
Test Drug

ESKETAMINE

Participate Sites
4Sites

Terminated4Sites

李信謙

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Psychiatry

2016-10-21 - 2018-11-19

Phase II

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered ALS-008176 Regimens in Adult Subjects Hospitalized with Respiratory Syncytial Virus

Condition/Disease

Respiratory Syncytial Virus (RSV)
Test Drug

ALS-008176 (JNJ-64041575)

Participate Sites
6Sites

Terminated6Sites

李岡遠

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2016-12-01 - 2018-06-30

Phase III

An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

Condition/Disease

Treatment-resistant Depression
Test Drug

ESKETAMINE

Participate Sites
8Sites

Terminated8Sites

李信謙

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Psychiatry

劉嘉逸

Linkou Chang Gung Medical Foundation

Division of Psychiatry

2015-07-01 - 2020-12-31

Phase III

Condition/Disease
Test Drug

Participate Sites
7Sites

Terminated7Sites

李岡遠

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

楊政達

Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2018-09-01 - 2022-03-31

Phase III

PONENTE: A multicenter, open-label, Phase 3b trial for adult patients with severe eosinophilic leukocyte asthma who are treated with high-dose corticosteroid inhalers, plus long-acting beta 2 agonists and oral corticosteroids for long-term treatment, to evaluate subcutaneously Efficacy and safety of 30 mg injection of Benralizumab for reducing oral corticosteroid dosage

Condition/Disease

Severe eosinophilic leukocyte asthma
Test Drug

Benralizumab

Participate Sites
8Sites

Recruiting8Sites

李岡遠

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

郭漢彬

Taipei Medical University Hospital

Division of Thoracic Medicine

2018-12-01 - 2024-06-21

Phase I

A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab in Combination With Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non Small Cell Lung Cancer (NSCLC) (MAGELLAN)

Condition/Disease

NSCLC
Test Drug

Durvalumab

Participate Sites
9Sites

Recruiting8Sites

李岡遠

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

楊政達

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-01-17 - 2020-04-30

Phase I

An Extension Study of T-1101 (Tosylate) Administered Orally to Patients With Advanced Refractory Solid Tumors

Condition/Disease

Advanced Refractory Solid Tumors
Test Drug

T-1101 (Tosylate)

Participate Sites
5Sites

Suspended4Sites

趙祖怡

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

2015-06-01 - 2018-09-30

Phase II

A Phase 2, randomized, multiple-dose, double-blind, placebo-controlled study of JKB-122 in treating subjects with non-alcoholic fatty liver disease (NAFLD)

Condition/Disease

non-alcoholic fatty liver disease (NAFLD)
Test Drug

JKB-122

Participate Sites
7Sites

Terminated7Sites

陳明堯

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

黃怡翔

Taipei Veterans General Hospital

2018-06-08 - 2021-01-31

Phase II

A Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-TIGIT Antibody, In Combination With Atezolizumab In Chemotherapy-Naïve Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Condition/Disease

Non-Small Cell Lung Cancer
Test Drug

MTIG7192A (RO7092284)

Participate Sites
6Sites

Terminated6Sites

李岡遠

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

江起陸

Taipei Veterans General Hospital

Division of Thoracic Medicine

Search Result

List